A comprehensive evaluation of apixaban in the treatment of venous thromboembolism

@article{Koehl2020ACE,
  title={A comprehensive evaluation of apixaban in the treatment of venous thromboembolism},
  author={Jennifer Koehl and B. Hayes and H. Al-Samkari and R. Rosovsky},
  journal={Expert Review of Hematology},
  year={2020},
  volume={13},
  pages={155 - 173}
}
  • Jennifer Koehl, B. Hayes, +1 author R. Rosovsky
  • Published 2020
  • Medicine
  • Expert Review of Hematology
    • ABSTRACT Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more convenient and accessible alternatives to warfarin or parenteral agents for the treatment of venous thromboembolism (VTE). Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is approved for the acute treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) as well as for the reduction in the risk of recurrent DVT and PE following initial therapy. Areas covered: This… CONTINUE READING
    View on Taylor & Francis
    ncbi.nlm.nih.gov

    References

    SHOWING 1-10 OF 118 REFERENCES
    New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
    • 32
    • PDF
    Oral apixaban for the treatment of acute venous thromboembolism.
    • 1,526
    • PDF
    Apixaban for extended treatment of venous thromboembolism.
    • 923
    • PDF
    Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    • 98
    Direct oral anticoagulants in hypercoagulable states
    • 21
    Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
    • 55
    Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
    • 240
    Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    • 1,574
    • PDF
    Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
    • 218
    New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
    • 192
    • PDF